問卷

TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Pediatrics

更新時間:2023-09-19

林曉娟Lin, Hsiao-chuan
  • Co-Principal Investigator
  • Clinical Trial Experience (year) 22 years 9 個月

篩選

List

11Cases

2022-10-11 - 2024-12-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2022-12-01 - 2025-08-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2018-06-01 - 2024-12-31

Phase III

Completed
A Phase III, Multiple-center, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Immunogenicity, and Safety of an Adjuvanted Inactivated Enterovirus 71 (EV71) Vaccine in Healthy Infants and Children
  • Condition/Disease

    Enterovirus 71 (EV71)

  • Test Drug

    nactivated EV71 whole viral particles adjuvanted with aluminum (Al(OH)3)

Participate Sites
7Sites

Terminated7Sites

2014-03-01 - 2016-03-31

Phase II

An Open-Label, Dose-Finding, Phase II Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine in Paediatric Subjects aged 3 to 6 years and 2 to 35 months old
  • Condition/Disease

    Prevention of Enterovirus 71 infection

  • Test Drug

    EV71 vaccine

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

2019-01-01 - 2020-12-31

Others

A Phase III Study of Immunogenicity and Safety Evaluation of AdimFlu-S (QIS) Quadrivalent Inactivated Influenza Vaccine in Healthy Subjects Aged 6 Months Old to 35 Months Old
  • Condition/Disease

    Influenza

  • Test Drug

    AdimFlu-S Quadrivalent Inactivated Influenza Vaccine(AdimFlu-S(QIS))

Participate Sites
9Sites

Recruiting8Sites

2010-10-01 - 2011-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2017-05-15 - 2019-05-31

Others

Immunogenicity and safety study of two formulations of GlaxoSmithKline (GSK) Biologicals’ human rotavirus (HRV) vaccine (444563), in healthy infants starting at age 6-12 weeks.
  • Condition/Disease

    Active immunisation of infants against gastroenteritis (GE) due to rotavirus (RV).

  • Test Drug

    HRV PCV-free vaccine

Participate Sites
6Sites

Terminated6Sites

2016-03-01 - 2018-10-31

Phase II

A phase II observer-blind, multicentre, dose-ranging study of children 6 to less than 36 months of age who are to be primed with a 2-dose series of GSK Biologicals’ AS03-adjuvanted A/Indonesia/05/2005 (H5N1) vaccine
  • Condition/Disease

    Active immunization against influenza A virus H5N1 subtype

  • Test Drug

    GlaxoSmithKline (GSK) Biologicals’ Influenza A/Indonesia/05/2005 (H5N1) vaccine adjuvanted with AS03

Participate Sites
8Sites

Terminated7Sites

2022-12-01 - 2025-08-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2022-10-11 - 2024-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2